irinotecan has been researched along with lactic acid in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 17 (89.47) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Luan, LB; Wu, QL | 1 |
| Atyabi, F; Azizi, E; Dinarvand, R; Ebrahimnejad, P; Jaafari, MR; Nomani, AR; Rad-Malekshahi, M; Sajadi, A | 1 |
| Atyabi, F; Dinarvand, R; Ebrahimnejad, P; Jafari, MR; Tabasi, SA | 1 |
| Ding, LY; Guo, M; Liu, YQ; Lu, Y; Ron, WT; Song, FF; Wang, Y; Yu, SQ | 1 |
| Calis, S; Dimchevska, S; Geskovski, N; Goracinova, K; Kajdžanoska, M; Kuzmanovska, S; Petruševski, G; Simonoska Crcarevska, M; Ugarkovic, S | 1 |
| Guo, M; Hou, J; Lu, Y; Rong, WT; Wang, DF; Wang, Y; Xu, Q; Yu, SQ | 1 |
| Dishman, AF; Lahann, J; Park, TH; Rahmani, S | 1 |
| Atyabi, F; Dinarvand, R; Ghahremani, MH; Khoshayand, MR; Montazeri, H; Ostad, SN; Rouhani, H; Sepehri, N; Tavassolian, F | 1 |
| Hou, J; Lu, Y; Qi, SS; Rong, WT; Wang, DF; Xiao, Q; Xu, Q; You, J; Yu, SQ; Zhang, J | 1 |
| Agarwal, P; He, X; Lu, X; Wang, H; Xu, RX; Yu, J; Zhao, S | 1 |
| Daoud, J; Essa, S; Lafleur, M; Martel, S; Tabrizian, M | 1 |
| Ambrosio, L; Biondi, M; Borzacchiello, A; De Rosa, G; Giarra, S; Mayol, L; Russo, L; Serri, C; Zeppetelli, S | 1 |
| Amini, M; Atyabi, F; Baharian, A; Dinarvand, R; Ghahremani, MH; Gharghabi, M; Mehdizadeh, M; Ostad, SN; Rouhani, H; Sepehri, N; Varshochian, R | 1 |
| Huang, YC; Lee, WH; Liu, SC; Liu, SJ; Su, CH; Tseng, YY; Wang, YC; Yang, ST | 1 |
| Emami, J; Hasanzadeh, F; Maghzi, P; Mirian, M; Rostami, M; Sadeghi, H | 1 |
| Gao, Z; Li, Z; Wang, P; Yan, J | 1 |
| Ahmad, N; Ahmad, R; Alam, MA; Jalees Ahmad, F; Umar, S | 1 |
| Fu, X; Mao, L; Qiu, YD; Tang, N; Xie, WQ | 1 |
19 other study(ies) available for irinotecan and lactic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[Preparation and characterization of 7-ethyl-10-hydroxycamptothecin-loaded hypomicron of amphiphilic block copolymer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Carriers; Irinotecan; Lactic Acid; Microspheres; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Solubility; Technology, Pharmaceutical | 2007 |
Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines.
Topics: Buffers; Camptothecin; Cell Death; Drug Delivery Systems; Folic Acid; HT29 Cells; Humans; Irinotecan; Lactic Acid; Microscopy, Fluorescence; Nanoparticles; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2010 |
Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Drug Carriers; Folic Acid; Injections, Intravenous; Irinotecan; Lactic Acid; Molecular Structure; Nanoparticles; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Surface Properties; Tissue Distribution | 2011 |
Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Emulsions; Humans; Irinotecan; Lactic Acid; Materials Testing; Nanocapsules; Nanoparticles; Neoplasms, Experimental; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Vitamin E | 2012 |
Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO-PPO-PEO nanoparticles using OFAT experiments.
Topics: Adsorption; Animals; Caco-2 Cells; Camptothecin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Lactic Acid; Male; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Propylene Glycols; Rats; Rats, Wistar; Structure-Activity Relationship; Surface Properties; Time Factors; Tissue Distribution; Tumor Cells, Cultured | 2013 |
Mechanisms of chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin.
Topics: Absorption; Animals; Caco-2 Cells; Calorimetry, Differential Scanning; Camptothecin; Cell Death; Chitosan; Coated Materials, Biocompatible; Coumarins; Enterocytes; HT29 Cells; Humans; Intestines; Irinotecan; Kinetics; Lactic Acid; Male; Nanoparticles; Particle Size; Perfusion; Permeability; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Rhodamine 123; Spectroscopy, Fourier Transform Infrared; Static Electricity; X-Ray Diffraction | 2013 |
Multimodal delivery of irinotecan from microparticles with two distinct compartments.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Delayed-Action Preparations; Dextrans; Hydrogen-Ion Concentration; Irinotecan; Lactic Acid; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2013 |
SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Humans; Irinotecan; Lactic Acid; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Surface Properties; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
TPGS2k/PLGA nanoparticles for overcoming multidrug resistance by interfering mitochondria of human alveolar adenocarcinoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lactic Acid; Mitochondria; Nanoparticles; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Vitamin E | 2015 |
Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chitosan; Doxorubicin; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Endocytosis; Humans; Hyaluronic Acid; Hydrogen-Ion Concentration; Intracellular Space; Irinotecan; Lactic Acid; Male; Mice, Nude; Nanoparticles; Neoplastic Stem Cells; Poloxamer; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spheroids, Cellular; Tissue Distribution | 2015 |
SN-38 active loading in poly(lactic-co-glycolic acid) nanoparticles and assessment of their anticancer properties on COLO-205 human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lactic Acid; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2015 |
Spontaneous arrangement of a tumor targeting hyaluronic acid shell on irinotecan loaded PLGA nanoparticles.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Liberation; Humans; Hyaluronan Receptors; Hyaluronic Acid; Irinotecan; Lactic Acid; Molecular Targeted Therapy; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2016 |
Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Biotin; Camptothecin; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Female; Humans; Hydrogen-Ion Concentration; Irinotecan; Kinetics; Lactic Acid; MCF-7 Cells; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2017 |
Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Brain; Brain Neoplasms; Camptothecin; Cisplatin; Disease Models, Animal; Drug Delivery Systems; Ethylnitrosourea; Glioblastoma; Glioma; Humans; Irinotecan; Lactic Acid; Male; Nanofibers; Neurosurgical Procedures; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Tumor Burden | 2016 |
PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan.
Topics: Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; HT29 Cells; Humans; Irinotecan; Lactic Acid; Liver Neoplasms; Micelles; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglactin 910; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Tretinoin | 2018 |
Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Delivery Systems; Fluorouracil; Humans; Hyaluronic Acid; Irinotecan; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Stomach Neoplasms | 2017 |
Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Brain; Caco-2 Cells; Camptothecin; Chitosan; Drug Carriers; Humans; Intestinal Absorption; Irinotecan; Lactic Acid; Male; MCF-7 Cells; Nanoparticles; Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar | 2018 |
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Glucose; Glycolysis; Humans; Irinotecan; Lactic Acid; Leucovorin; Male; Mice, Nude; Mucin-1; Neoplasm Transplantation; Oxaliplatin; Pancreatic Neoplasms | 2020 |